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INTRODUCTION
Islet transplantation is used clinically for patients
with diabetes mellitus (especially for insulin-dependent
Diabetes Mellitus, type 1DM) as a radical therapy,
instead of regular insulin injection (1). One of themajor
obstacles to utilizing islet transplantationmore routinely
is its useof allogeneicgrafts.This isbecausetheallogeneic
graft is sometimes rejected by the recipient’s immune
system in spite of immunosuppressive drugs and new
regimen (1). Thus, a primary goal for improving allo-
geneic islet transplantation is tomake theeternal trans-
planted islets less invasive in character so that the graft
can survive without immunosuppression.
Many studies have shown that the liver has a great
potential to induce immunological tolerance. It also
showed that the liver represented one of the immu-
nologically privileged site for transplantation (2). Thus,
the transportal islet transplantation system has been
used frequently, both experimentally and clinically
(3, 4). According to Griffith et al. (5) islets transplanted
from the portal vein migrate into the hepatic paren-
chyma five or six days after transplantation. As for other
sites of islet transplantation, several studies have sug-
ORIGINAL
Donor-specific tolerance inducedby simultaneousallogeneic
islet transplantation with CD4+CD25+ T-cells into hepatic
parenchyma in mice
Tetsuya Ikemoto1, Seiki Tashiro1, Koji Yasutomo2, Kenji Kishihara2, Nobuhiro Kurita1,
and Hidenori Miyake1
1Department of Digestive and Pediatric Surgery, and 2Department of Immunology and Parasitology,
The University of Tokushima School of Medicine, Tokushima, Japan
Abstract : Background. The allogeneic islets transplantation is an ideal therapeutic strategy
for patients with diabetes mellitus. However, it has been difficult to induce immunological
tolerance against islets grafts. TheCD4+CD25+ regulatory T-cells (Treg)play a role in suppressing
T-cell activation. Thus, we evaluated whether Treg can regulate donor-specific T-cell tolerance
that received allogeneic islets into the hepatic parenchyma (ITxHP) along with Treg.
Methods. C3 H/He mice were used as donors ; and streptozotocin-induced diabetic BALB/c mice
were recipients. The protocol included three groups : Group A recipients received only 300
IE islets ; Group B was given 300 IE islets and whole splenocytes ; Group C was given 300
IE islets and Treg purified from peripheral lymph nodes.
Results. For all mice in Groups A and B, the fasting blood sugar exceeded 250mg/dl and graft
rejection was observed. GVHD was observed earlier in Group B than in Group A. In contrast
graft survival exceeded 30 days for two mice in Group C (50%, mean POD 28.5±24.0, P<0.05).
Mixed lymphocyte reaction showed that T-cells from tolerant mice had very weak responses
against spleen cells from C3H mice.
Conclusions. Thesimultaneous ITxHPwithCD4+CD25+ T-cells administrationprolongedisletgraft
survivals and induced donor-specific hyporesposiveness. J.Med. Invest.51 :178-185,August,2004
Keywords : islet transplantation, experimental transplantation, donor-specific tolerance, CD4+CD25+ T-cells, mouse
Received for publication February 10, 200４; accepted February
19, 2004.
Address correspondence and reprint requests to Tetsuya Ikemoto,
M.D., Department of Digestive and Pediatric Surgery, Institute of
Health Biosciences, The University of Tokushima Graduate School,
Kuramoto-cho, Tokushima 770-8503, Japan and Fax : +81-88-631-
9698.
The Journal of Medical Investigation Vol. 51 2004
１７８
gested direct transplantation of islets into hepatic pa-
renchyma, although the transplantation efficiency is
not good (6). However, considering the great potential
of liver to induce immunological tolerance by itself (7),
the possibility can allow the less invasive technique
like percutaneous administration (8), we have tried
here to establish direct islet transplantation into the
hepatic parenchyma system.
It is well known that immunological tolerance can
be acquired by transfer of donor-specific antigens into
the recipient beforehand (9, 10). Many experiments
have suggested that T-cells play an important role in
inducing such a tolerant state (11, 12), and one of them
showed that T-cells from untreatedmice could prevent
acute allograft rejection (13). Hara et al. have recently
shown that CD4＋CD45RBlow and CD4＋CD25＋ T-cell
subpopulations isolated from animals with long-term
surviving allografts cancontrol rejectionof skin allografts
(14). Those studies suggest that donorMHCor antigen-
specific regulatory T cells could be generated before
transplantation and could then afford graft protection.
However, it is not practical to prime regulatory T-cells
before transplantation and use them in clinical islet
transplantation because freshly isolated islets are rec-
ommended (22). We have to try to minimize the cold
ischemia of islet (4). Thus, we examinedwhether un-
primed donor-derived CD4＋CD25＋regulatory T-cells
(Treg) could control allogeneic islet transplantation.
We aimed to show whether donor-derived Treg could
induce allograft-specific T-cell tolerance, resulting in
long-term survival of allogeneic islets.
MATERIALS AND METHODS
Animals
C3H/He male (8 -10 weeks old) and BALB/c male
(6 -7 weeks old) were purchased from Japan CLER
Co., Tokyo. Three C3H/Hemicewere used as donors.
BALB/c mice were injected intraperitoneally with 200
mg/kg Streptozotocin (STZ,WAKOpure chemical in-
dustries, Ltd, Tokyo, Japan.). Onlymice whose fasting
blood sugar level (FBS level) exceeded 350mg/dl with
polyuria and polyposia after the 6th day of the medi-
cation were used as recipients. Thesemice were usu-
ally fed with CE-2 solid food (JapanCLERCo ; Tokyo,
Japan) and drinking water was given freely. All ex-
periments were conducted in accordance with the
animal experimental guidelines of The University of
Tokushima.
Preparation of islets
Islet isolation was carried out using the collagenase
technique (15) and centrifugation on a Ficoll gradient
(16). Briefly, an upper middle incisionwasmade in the
abdomen of the donormouse under general anesthesia,
and the distal end of the common bile duct (CBD) was
clamped. The CBD was punctured carefully by a 27-
gauge needle, and pancreas tissue was flowed back
to retrograde with 2.5ml of Hanks Balanced Salt So-
lution (HBSS, SIGMA CHEMICAL CO, St Louise,
U.S.A.) that contained 1mg/ml collagenaseS-1(SIGMA
CHEMICAL CO, St Louis, U.S.A.), in order to inhibit
the pancreas tissue mechanically. The donors were
sacrificed after extracting the pancreas. These proce-
dures were undergone under a lightmicroscope. After
extraction of the pancreatic tissue, the tissue was in-
cubated for 35minutes at 37 degrees in a shakerwater
bath. After washing three times (1500rpm, 4℃, 5min.),
impurities were removed by a sterile stainless steel
mesh and the islets were separated by a Ficoll gradient
(WAKO pure chemical industries, Ltd, Tokyo, Japan.
Specific gravity1.023, 1.033, 1.043, and 1.050 ; 2200 rpm,
4℃, 10 min.). The antibiotics Penicillin and Strepto-
mycin (ICNBiomedicals Inc., Ohio, U.S.A.) were added
to RPMI 1640 (SIGMA CHEMICAL CO, St Louise,
U.S.A.) in a total volume of 50 µl, along with 300 IE
(islet equivalent) islets, after removal of the exocrine
pancreatic tissue by the handpickingmethod. All pro-
cedures involving cell adjustments were performed
on a clean bench at room temperature.
Transplantation
Transplantation was performed under general an-
esthesia. All recipient mice received an upper midline
lapatomy. The hepatic parenchyma of the right lobewas
punctured carefully with a 30-gauge needle to 1mm
depth, and islets were transplanted from a 1ml syringe.
The total injection volume was adjusted to less than
0.1 ml. To prevent leakage of islets out of the hepatic
parenchyma, we injected the fluid over 90 seconds.
After removal of the needle, gentle pressure was applied
for threeminutes with a sterile swab for hepatic hemo-
stasis at the puncture point. The abdomenwas closed
using two layers (peritoneum and fascia, 3-0 vicryl ;
skin, 3-0 nylon). The operation was performed in a
sterile environment. All of the postoperativemicewere
wormed for10 minutes, and then they were returned
to the cage, where drinkingwater and solid feed were
given freely.
Preparation of lymphocytes
Three C3H/Hemice 8-10 weeks of age were eutha-
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nized. The spleenand themesenteric and inguinal lymph
nodes were extracted from each. After carrying out
homogenization with 3ml RPMI 1640 that contained
10% heat-inactivated fetal bovine serum (FBS), hemo-
lyzation of the spleen and the lymph nodes was per-
formed using 7% NH4Cl, and the lymphocytes were
washed and spun down (1500rpm, 4℃, 5min. twice).
The viable lymphocytes were counted under a light
microscope after dyeing dead cells in Turk solution
(WAKO pure chemical industries, Ltd, Tokyo, Japan),
and splenocytes were adjusted to 1.0×108(10µl). Af-
terwards, CD4＋CD25＋T-cells were purified from pe-
ripheral lymph nodes by positive selection usingMag-
netic Cell Separation (MACS) procedure with an anti-
CD25 antibody (e-bioscience, U.S.A) andGoat anti-rat
IgG microbeads (Militienyi Biotec, Germany). CD4＋
CD 25＋ T-cells were adjusted to 1.0×105(10µl). These
splenocytes and purified lymphocytes were used im-
mediately for transplantationwith islets.All procedures
were completed within two hours. All pre-and post-
purified lymphocytes were investigated for contents
of lymphocyte populations by FACSCalibur (BD Bi-
osciences, U.S.A.).
Criteria for rejection
FBS levels of all recipients were measured two or
three times per week, starting from the day of trans-
plantation, by the tail cut method (using Precision
Q.I.E, Medisense, Coleshill, U.K). Two consecutive
days of a high blood glucose level (over 250mg/ml)
were judged to indicate rejection of the transplanted
islets.
Experimental design
The protocol included three treatment groups :
Group A (n=5), recipient mice receiving only 300 IE
islets as a control ; Group B (n=5), recipients given 300
IE islets and whole splenocytes (1.0×108), as already
described ; Group C (n=4), recipients given 300 IE
islets and CD4＋CD25＋T-cells (1.0×105) purified from
inguinal lymph nodes and mesenteric lymph nodes.
For all recipients within each group, islets and lym-
phocytes were transplanted into the hepatic paren-
chyma (ITxHP) simultaneously. Immunosuppressive
agents were not given.
Mixed Lymphocyte Reaction (MLR)
In order to investigate whether or not donor-specific
tolerance was induced, a mixed lymphocyte reaction
(MLR) was performed. Stimulator splenocytes (from
C3H/He, BALB/cJClr and C57/BL6 as 3rd party)
were treatedwith 50µg/mlMitomycinC(MMC,Kyowa
Hakko Co ; Tokyo, Japan) at 37℃ for 45min. Using the
method of Goossens et al. (17), we separated the free
lymphocytes from the livers of the recipients whose
grafts survived over 30 days. These lymphocytes were
designated responders. Each set of stimulator and
responder cells (5.0×105) was added to 0.2mLRPMI
1640 mediumwith 100U/mLpenicillin, 0.1mg/ml strep-
tomycin and 10% heat-inactivated FBS. These cells were
add to round-bottom 96-well microplates and incubated
at 37℃ in 5%CO2. After 66 hours, 0.5µCi of [3H]meth-
ylthymidine was added to each well, and theMLR re-
sponse was determined by measuring incorporation
of [3H] methylthymidine by direct β counting (Scin-
tillation Counter, Aloka Co ; U.S.A.). The results were
reported as themean counts perminute (cpm) of trip-
let measurements. The stimulation indices (S.I.s) were
calculated by the formula : S.I.=cpm (mean experi-
mental culture)/cpm (nave BALB/c culture). The
Median test was used for the statistical analysis.
Histological examination
Several of the recipients were sacrificed, their livers
bearing transplanted islets were extirpated without
perfusion, and histological examinationwas performed.
One part of the sections was stained by Hematoxylin-
Eosin, and others were stained using an anti-insulin an-
tibody, in order to evaluate islet function (usingDAKO
LSAB2 kit/HRP, DAKO Cytomation Co ; U.S.A.).
Frozen sections
Isolated islets were also stained by 5 (and 6)-carboxy
fluorescein diacetate succinimidyl ester (CFSE ; pur-
chased fromMolecular Probes, Eugene, OR) in order
to estimate location and function of the transplanted
islets (30). Isogeneic transplantation (BALB/c to
BALB/c) was used for this model. Isolated islets were
allowed to float in 4 ml Phosphate Buffered Saline
(PBS) to whichwas added 4mMCFSE. The isletswere
left floating for 10 min. at room temperature. After
washing with RPMI 1640 medium three times (1500
rpm, 4℃, one min.), these islets were transplanted as
described earlier. After 14 POD, livers bearing trans-
planted islets were extirpated without perfusion,
mounted in O.C.T. compound (Miles Laboratories,
Inc. Elkhart, Indiana), and frozen in liquid nitrogen.
Frozen sections of the liver were made in the Cryostat
at -24℃. All sections were observed under a fluores-
cence microscope, and sections that contained islets
were stained by an anti-insulin antibody and by He-
matoxylin.
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RESULTS
Prolonged graft survival achieved by ITxHP with Treg
We first examined whether direct injection of islet
cells into hepatic parenchyma induces stable engraft-
ment of functional islets. The islets fromBALB/cmice
were transplanted into the hepatic parenchyma of
BALB/c mice that had been treated by STZ, and fast-
ing blood sugar (FBS) levels in peripheral bloodwere
monitored. The FBS of mice that had been treated by
STZ began to increase 4-6 days after treatment, and
never decreased to less than 250mg/ml (data not
shown). In contrast, the FBS of STZ-treatedmice that
received 300 IE islets into the hepatic parenchyma
showed reduced hyperglycemia, and achieved nor-
moglycemia within seven days of transplantation. Their
FBS never increased above 250mg/ml to at least 50
days following transplantation (data not shown). These
results show that direct injection of islets into thehepatic
parenchyma successfully induces stable engraftment of
functional islets. Using this transplantation system, we
examined whether donor-derivedCD4＋CD25＋ T-cells
control allogeneic islet transplantation into hepatic
parenchyma.
After islet transplantation into the hepatic paren-
chyma (ITxHP), all recipients were monitored for
FBS levels and were examined for rejection or the ap-
pearance of clinical GVHD two or three times a week
(Table 1, Figure1). For all mice in the control group
(Group A : The 300 IE islets fromC3Hmicewere trans-
planted into BALB/c mice), the FBS level descended
to less than 250 mg/dl within seven postoperative days
(PODs), and FBS levels began to increase around the
20 th postoperative day (Figure 1). All of these grafts
were rejected on POD20.0±2.1. For all mice in Group
B (who received simultaneous ITxHP with 1.0×108
whole splenocytes), increased FBS levels were ob-
served within 10 PODs (Table 1), and clinical obser-
vations included depilation and profuse diarrhea. The
graft was rejected on POD 10.6±4.5 (Table 1). These
results showed that co-transfusion of total splenocytes
without immunosuppression aggravatesGVHD. This
was consistent with previous reports of co-injection
of total splenocytes with allo-transplantation through
the portal vein without immunosupression from agents
such as FK506 (18). In the case of Group C (mice that
received simultaneous ITxHP with 1.0×105 Treg pu-
rified from peripheral lymph nodes), two of the four
mice achieved normoglycemia after the 30 th postop-
erative day (Figure 2). Graft survival was significantly
prolonged (mean POD 28.5±24.0, P＜0.05) compared
to the control group (Group A) (Table 1). Themodes
of FBS levels after transplantation were completely
different between Groups A andC (Figure 1). Briefly,
the FBS level of Group A had never decreased below
Table 1. All transplantations (with or without lymphocytes) were performed directly into the hepatic parenchyma. Group A,
rejection was occurred at 20±2.1 POD. On the contrary, in Group B, rejection was accelerated, and fatal GVHD was observed. In
two mice from Group C (IT×HP with CD 4＋CD 25＋ T-cells purified from peripheral lymph nodes) grafts survival exceeded 30 post-
operative days. However, as in Group B,fatal GVHD was observed in two mice from Group C.
Group Donor lymphocyte n Graft survival (days) Mean±SD
A 0 5 18, 18, 20, 21, 23 20.0±2.1
B 1.0×107 5 7＋, 7, 8＋, 15, 16 10.6±4.5
C 1.0×105 4 10＋, 12＋, 30＊, 62 28.5±24.0
＊ : sacrificed for immunological and histological examinations. ＋ : death of an individual mouse (fatal GVHD) occurred. There were
significant differences between total graft survival days between Groups A and C and Group B and C, according to Dunn’s test.¶ :
P＜0.001, ∆ : P＜0.05.
Figure 1. Graft survivals of transplanted islets. FBS measure-
ments of all cases of Group A (control group) and twomice inGroup
C (excepted two mice because of fatal GVHD) are shown. FBS
measurements for the control group (GroupA)hadnever decreased
below 250mg/dl after rejection. Double line in both graphs is 250
mg/dl, i.e. the rejection criteria as described. POD, Post Operative
days. FBS, fasting blood sugar. The triangle on the graphs shows
the day of the transplantation.
∆
¶
The Journal of Medical Investigation Vol. 51 August 2004 １８１
250 mg/dl after graft rejection around POD20.On the
other hand, the FBS levels of two mice in Group C
(long-term survivors) approached normoglycemia
gradually around POD11 and never rose above 250
mg/dl during the observation period (up to POD30).
The highly purified Treg prolonged graft survival
In Group C, Treg were transferred with islets into
hepatic parenchyma but the rate of graft survival was
significantly different. The major difference was the
purity of the CD4＋CD25＋ T-cells. The absolute num-
bers of CD4＋CD25＋ T-cells in Group C were set to
be the same, but the purity of eachsamplewasdifferent
(Figure 2). In all of the Group C samples, the purity
of CD4＋CD25＋ T-cells was more than 70% after the
magnetic cell sorting (MACS) procedure. However,
the purity of cell populations other thanCD4＋CD25＋
T-cells was also different in Group C. The percentage
of CD4＋CD25－ T-cells in eachGroupC sample ranged
from 4.2% to 14.4%, and the recipients receiving Treg
that were highly contaminated with CD4＋CD25－ T-
cells did not acquire long-termgraft survivals (Figure 2).
These findings showed that highly pure CD4＋CD25＋
T-cells that contain little contamination by CD4＋CD
25－ T-cells are required to prolong islet graft survival.
ITxHP with highly purified Treg induced donor-specific
T-cell tolerance
We examined whether transplanted Treg induced
donor-specific T-cell toleranceusingamixed lymphocyte
reaction (MLR). Free liver lymphocytes from long-term
graft survival recipients were used as responders and
splenocytes from BALB/c, C3H/He, and C57BL/6
mice were used as stimulators (Figure 3). The reaction
of T-cells from BALB/cmice against spleen cells from
C3 H/He (Donor strain) or C57/BL6 (3rd party)mice
was shown by S.I. values of 10.3 and 12.2, respectively
(S.I., formula was already described) (Figure3, left
pair). In contrast, the reaction of T-cells from the liver
of a recipient in Group C (simultaneous ITxHP with
Treg purified from peripheral lymph nodes) to C3H/
He (Donor strain) or C57/BL6 (3rd party) mice was
indicated by S.I. values of 2.06 and 6.12, respectively
(Figure 3, right pair. S.I., significant difference. P＜0.05).
These results show that donor-specific tolerance (hy-
poresponsiveness) was induced, at least in recipient
liver, on POD 30 for Group C (simultaneous ITxHP
with Treg purified from peripheral lymph nodes).
Functioning transplanted islets surrounded by hepa-
tocytes
Finally, we examined the site where transplanted
islets were present in the hepatic parenchyma. His-
tological examinationswere performed for the BALB/c
to BALB/c isograft transplantation model on POD14,
and for mice receiving simultaneous allogeneic ITxHP
with Treg purified from lymph nodes on POD32. The
recipient’s livers were stainedwith Hematoxylin-Eosin
Figure 3. MLR in lymphocytes from long-survivingmice in group
C. MLR was performed as described in Materials and Methods.
The responses of lymphocytes from nave BALB/cmice to lympho-
cytes of C3H/He (donors) and C57/BL6 were not significant. On
the other hand, responses of lymphocytes from long-surviving
mice (Group C) to donor cells were significantly suppressed, even
though the responses to third party cells were maintained (* ;
significant difference. P＜0.05).
Figure 2. I-IV. All cases of CD4＋CD25＋T-cells purification from
peripheral lymphnodes (Group C) was showed. CD4＋CD25＋T-
cells ratio of purification by MACS was over 70%. However, extra
CD 4＋CD 25＋ T-cells, especially CD4＋CD25－ T-cells, were not
stable (UL, upper left area of the graphs). The graphs show that
over 70% of CD 4＋CD 25＋T-cells purification with less than 10%
contamination by CD4＋CD25－ T-cells was required to achieve
long-term survival of islet cells. MACS,Magnetic cell separation.
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and examined under a light microscope. The liver had
small crevasse on its surface, and cell clusters that are
not normally found in liver were present in the cre-
vasses (Figure 4 a). In order to estimate if the cell
clusters were transplanted islets, we stained BALB/c
islets with CFSE and transplanted them into STZ-
induced BALB/c hepatic parenchyma. Then we ex-
amined the frozen sections of recipient livers on POD
14 under a fluorescence microscope and subsequently
stained them with both anti-insulin antibody and He-
matoxylin. TheCFSE labeled isletswere localized in the
same area of cell clusters found in the crevasses (Figure
4 b). Furthermore, these cell clusters were positive
for insulin, which demonstrated that the transplanted
islets were localized in the small crevasses of hepatic
parenchyma and were producing insulin (Figure 4c).
DISCUSSION
Allogeneic islet transplantation has been considered
an ideal therapeutic strategy for patients with diabetes
mellitus, compared with insulin supplementation (1).
However, the major obstacle to islet transplantation
is the induction or maintenance of immunological
tolerance to allogeneic islet grafts. Although this prob-
lem is partially addressed by the use of a strong im-
munosuppression agent such as FK 506, or by effective
immunosuppressive methods such as the Edmonton
protocol (4), transplanted islets are sometimes rejected.
Various experimental approaches have been used for
the induction of immunological tolerance, including
infusion of donor specific antigen via the portal vein
(19), anti-IL 2 receptor antibody (20) or regulating the
CTLA-4 pathway (21). We have demonstrated in an
allogeneic rat small intestine transplantation model
that the infusion of total splenocytes via the portal vein
before transplantation allows allogeneic grafts to sur-
vive in the recipients under immunosuppression (18).
Other groups have shown that the transfer of T-cells
from rodents that received allogeneic spleen cells regu-
lated T-cell tolerance against allogeneic grafts. However,
it is not practical to transfuse allogeneic cells before
clinical transplantation. Generally surgeons try tomini-
mize the period of cold ischemia for organs. As effective
islet transplantation, freshly isolated islets are recom-
mended (so-called Edmonton protocol (22)). In order
to overcome this problem, we attempted here to use
donor-derived nave lymphocytes, especially Treg to
inhibit the host immune system response against islet
grafts. The co-injection of Treg with allogeneic islets
into the hepatic parenchyma could induce graft-specific
T-cell tolerance, and could also allows grafts to survive
in the parenchyma. It is hoped that this procedure of
islet transplantationwill provide a basis for establishing
a new clinical protocol for allogeneic islet transplantation.
Treg are known to inhibit autoreactive T-cells as well
as T-cell responses against several infectious organisms
(23). Several recent papers have shown that Treg from
mice that have received allogeneic cells have a strong
ability to inhibit T-cell responses against a subsequent
allogeneic graft (24). Also, one paper has shown that
donor-derived Treg are able to inhibit responses to
allogeneic skin grafts (11). In the present study, we
used donor-derived Treg in order to control allogeneic
islet grafts, and the Treg were capable of inducing
donor-cell-specific T-cell tolerance. The purity of CD4＋
CD25＋ T-cells ranged from 70-80% when peripheral
lymph node cells were used as a source of Treg.When
the Treg fraction was contaminated by a significant
number of T-cells other than Treg, the contaminating
cells induced rejection of grafts instead of tolerance.
For example, we observedGVHD in twomice in Group
C and these mice died. Although Treg purified from
lymph nodeswere adjusted to include the samenumber
of cells for all Group C samples, the number of cells
other than Treg given to theGVHDgroupwas higher
than in other samples. These results suggest that al-
logeneic conventional T-cells were activated by rec-
ognizing MHC expressed on transplanted islets in the
Figure 4. Figure 4a. Post-transplanted islets existed in a small
crevasse of hepatic parenchyma. hematoxylin and eosin,original
magnification×400.
Figure 4 b. Transplanted islets stained with CFSE. The islets were
found in the hepatic parenchyma. Frozen section, original mag-
nification×100.
Figure 4 c. Same section (Figure 4b) stained with insulin antibody.
The islet was shown by an arrow. Staining for insulin shows that
the islet cells were functioning well. Hematoxillin, original mag-
nification×100.
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GVHD group. This in turn suggests that the removal
of conventional T-cells is an important step for avoid-
ing fatal GVHD in this model system.
The T-cells in livers frommice that received allogeneic
islets and Treg have very weak responsesagainst spleen
cells from donor C3H mice, indicating that T-cells in
these recipients acquired tolerance against islet grafts.
Whether or not this tolerance ismaintained by the per-
sistent presence of donor-derived Tregwill be clarified
by future experiments. The T-cells responses from
ITxHP mice against spleen cells from C57BL/6mice
were low. Themajority of T-cells in the liver express the
T-cell receptor at intermediate levels (17). Thus, the
magnitude of their response would be relatively low
compared with conventional T-cells.
We report here transplantation of islets directly into
the hepatic parenchyma. Several previous papers have
reported attempts to use the hepatic parenchyma (di-
rectly and intraportally) as a site of isogeneic islet trans-
plantation (4, 6). Rogers et al , described a ‘strange’
phenomenon of intraportal transplanted islets moving
into the hepatic parenchyma a few days after trans-
plantation (5).Moreover, some stated that direct intra-
hepatic transplantation had advantages with respect
to insulin release (25), andwas a safe andeasy technique
(26). Moreover, this could allow for less invasive tech-
nique like percutaneous administration. Indeed, in clini-
cal transplantation, intraportal transplantation may be
accompanied by serious complications due to portal
hypertension (portal embolism) and intrahepatic bleed-
ing, as various rate of complication and measures are
reported (27-29). With this in mind, we chose direct
hepatic transplantation in order to avoidportal embolism
caused by injection of a relatively large volume of cells
(T-cells and islets). We found that islets cell clusters
secreting insulin were located among the hepatocytes,
and this probably occurred through direct inoculation
rather than through the circulation. Islets transplanted
through portal veins are known tomigrate into hepatic
parenchyma (5). Thus, the final site where islets are
localized should be the same in islet transplantation
through portal veins as by direct transplantation to
the hepatic parenchyma. Considering that direct in-
jection into hepatic parenchyma is very easy and is less
invasive, compared with transportal transplantation,
this surgical procedure may be easily applied to clinical
islet transplantation.
In summary, the procedure of simultaneous ITxHP
with Treg can induce donor-specific tolerance, and it
allows islets to survive in hepatic parenchyma without
the use of immunosuppressive drugs. This experimen-
tal system forms a basis for future work to establish
a new clinical protocol for allogeneic islet transplantation.
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